These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26238619)

  • 1. Prostate cancer proteomics: The urgent need for clinically validated biomarkers.
    Evans CA; Glen A; Eaton CL; Larré S; Catto JW; Hamdy FC; Wright PC; Rehman I
    Proteomics Clin Appl; 2009 Feb; 3(2):197-212. PubMed ID: 26238619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.
    Al-Ruwaili JA; Larkin SE; Zeidan BA; Taylor MG; Adra CN; Aukim-Hastie CL; Townsend PA
    Cancer Genomics Proteomics; 2010; 7(2):93-103. PubMed ID: 20335524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics in diagnosis of prostate cancer.
    Davalieva K; Polenakovic M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of proteomics in prostate cancer research: biomarker discovery and validation.
    Pin E; Fredolini C; Petricoin EF
    Clin Biochem; 2013 Apr; 46(6):524-38. PubMed ID: 23266295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer biomarkers: an update.
    Romero Otero J; Garcia Gomez B; Campos Juanatey F; Touijer KA
    Urol Oncol; 2014 Apr; 32(3):252-60. PubMed ID: 24495450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biomarker Discovery of Colorectal Cancer Using Membrane Proteins Extracted from Cancer Tissues].
    Tomonaga T; Kume H
    Rinsho Byori; 2015 Mar; 63(3):322-7. PubMed ID: 26524855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New biomarkers in prostate cancer.
    Crawford ED; Ventii K; Shore ND
    Oncology (Williston Park); 2014 Feb; 28(2):135-42. PubMed ID: 24701701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
    Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer.
    Jedinak A; Loughlin KR; Moses MA
    Oncotarget; 2018 Aug; 9(65):32534-32550. PubMed ID: 30197761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic approaches for serum biomarker discovery in cancer.
    Maurya P; Meleady P; Dowling P; Clynes M
    Anticancer Res; 2007; 27(3A):1247-55. PubMed ID: 17593616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
    Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
    Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum markers for prostate cancer: a rational approach to the literature.
    Steuber T; O'Brien MF; Lilja H
    Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].
    Ohori M
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):6-10. PubMed ID: 19151558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.
    Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A
    Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer biomarker discovery using high performance mass spectral serum profiling.
    Oh JH; Lotan Y; Gurnani P; Rosenblatt KP; Gao J
    Comput Methods Programs Biomed; 2009 Oct; 96(1):33-41. PubMed ID: 19423179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer.
    Yocum AK; Khan AP; Zhao R; Chinnaiyan AM
    Proteomics; 2010 Oct; 10(19):3506-14. PubMed ID: 20821805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New circulating biomarkers for prostate cancer.
    Bensalah K; Lotan Y; Karam JA; Shariat SF
    Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness.
    Ahrens MJ; Bertin PA; Vonesh EF; Meade TJ; Catalona WJ; Georganopoulou D
    Prostate; 2013 Dec; 73(16):1731-7. PubMed ID: 23934862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular diagnosis of prostate cancer: are we up to age?
    Bhavsar T; McCue P; Birbe R
    Semin Oncol; 2013 Jun; 40(3):259-75. PubMed ID: 23806492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.